John Constant
Impact in
-
- Intensive Care Unit Cognitive Disorders
- Immunology top 10%
- Immune Response and Inflammation
- Inflammation biomarkers and pathways
Papers in
-
- S100 Proteins and Annexins 1
-
- Health Systems, Economic Evaluations, Quality of Life 2
- Pharmaceutical Economics and Policy 2
- Co-authors
- R. Bruce Light (2 shared papers)Lona Poole (2 shared papers)Stanley A. Nasraway (2 shared papers)Richard G. Wunderink (2 shared papers)Antonio Anzueto (2 shared papers)Guillermo Gutiérrez (2 shared papers)Robert N. Cooney (2 shared papers)Gerry S. San Pedro (2 shared papers)
- Journals
- Clinical Neuropharmacology (1 paper)Clinical Pharmacology & Therapeutics (1 paper)The Lancet (1 paper)Nature Reviews Drug Discovery (1 paper)Clinical and Translational Science (1 paper)
- Partner nations
- United StatesCanadaUnited Kingdom
In The Last Decade
John Constant
9 papers receiving 928 citations
Peers
Comparison fields: 5 of 92
- Critical Care and Intensive Care Medicine 156
- Immunology 353
- Epidemiology 469
- Clinical Biochemistry 71
- Nephrology 45
Countries citing papers authored by John Constant
This map shows the geographic impact of John Constant's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by John Constant with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites John Constant more than expected).
Fields of papers citing papers by John Constant
This network shows the impact of papers produced by John Constant. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by John Constant. The network helps show where John Constant may publish in the future.
Co-authors
The 25 scholars most cited alongside John Constant, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | Double-blind randomised controlled trial of monoclonal antibody to human tumour necrosis factor in treatment of septic shock. NORASEPT II Study Group. | 1998 | 490 |
| 2 | 1998 | 369 | |
| 3 | 2017 | 54 | |
| 4 | 2009 | 26 | |
| 5 | 2004 | 4 | |
| 6 | 2019 | 3 | |
| 7 | 2023 | 2 | |
| 8 | 2014 | 2 | |
| 9 | 2024 | 1 | |
| 10 | 2020 | 0 |
About John Constant
John Constant is a scholar working on Molecular Biology, Economics and Econometrics, Immunology, Epidemiology and Computational Theory and Mathematics, having authored 10 papers that have together received 951 indexed citations. Recurring topics across this work include Computational Drug Discovery Methods (2 papers), Health Systems, Economic Evaluations, Quality of Life (2 papers), Immune Response and Inflammation (2 papers), Pharmaceutical Economics and Policy (2 papers), Statistical Methods in Clinical Trials (2 papers), Sepsis Diagnosis and Treatment (2 papers), S100 Proteins and Annexins (1 paper) and Poisoning and overdose treatments (1 paper). The work is most often cited by research in Critical Care and Intensive Care Medicine (156 citations), Immunology (353 citations), Epidemiology (469 citations), Clinical Biochemistry (71 citations) and Nephrology (45 citations). John Constant has collaborated with scholars based in United States, Canada and United Kingdom. Frequent co-authors include R. Bruce Light, Lona Poole, Stanley A. Nasraway, Richard G. Wunderink, Antonio Anzueto, Guillermo Gutiérrez, Robert N. Cooney, Gerry S. San Pedro, Steve Berman and James E. Pennington. Their work appears in journals such as Clinical Neuropharmacology, Clinical Pharmacology & Therapeutics, The Lancet, Nature Reviews Drug Discovery and Clinical and Translational Science.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.